Hugel is a medical aesthetics company that sells botulinum toxin, fillers and skin boosters, and cosmetics.
According to the company's announcement on November 4, 2026, third-quarter 2026 sales by product were KRW 47.2 billion for botulinum toxin (down 21% year on year), KRW 30.9 billion for fillers and skin boosters (up 2%), and KRW 19.4 billion for cosmetics and other (up more than 25%).
In the same quarter, combined domestic sales of toxin, fillers and skin boosters rose 54% to KRW 27.4 billion, and sales in Europe and other regions rose 18% to KRW 17.8 billion. The main product is the botulinum toxin Letybo, sold in Korea as Botulax; it received U.S.
FDA approval in March 2024 and was launched in the U.S. in March 2025 through partner Veneb. For the first half of 2026, announced August 6, toxin sales were KRW 149.4 billion, up 46.6%, fillers and skin boosters reached KRW 66.1 billion, and cosmetics and other reached KRW 39 billion.
Overseas sales of toxin, fillers and skin boosters totaled KRW 162.1 billion in the same period, about 64% of revenue. Customers are clinics and med spas, and in the U.S. the company targeted about 80 strategic accounts first for direct sales.
The cosmetics unit is anchored by the clinical cosmetics brand Welaxe, which is expanding its U.S. presence. Competition is most intense in the Korean toxin market, while in the U.S. the domestic rival Nabota's maker maintains its partnership with Evolus, and in China Hugel holds a 22% share and ranks second.